Edwards Lifesciences Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss decreased by 8.3% to $1.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 71.1%, from $3.80M to $1.10M. This is a positive signal — lower values indicate better performance for this metric.
An increase may signal persistent market headwinds or credit quality concerns regarding the underlying securities.
The total accumulated unrealized losses on available-for-sale debt securities that have remained in a loss position for...
Standard long-term investment risk disclosure required for all major financial institutions.
other_debt_securities_available_for_sale_continuous_unre_23ad4c| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $3.20M | $5.50M | $30.00M | $60.00M | $54.10M | $48.20M | $38.30M | $25.60M | $17.90M | $12.70M | $6.80M | $5.20M | $3.80M | $2.70M | $1.90M | $1.20M | $1.10M |
| QoQ Change | — | — | — | — | +71.9% | +445.5% | +100.0% | -9.8% | -10.9% | -20.5% | -33.2% | -30.1% | -29.1% | -46.5% | -23.5% | -26.9% | -28.9% | -29.6% | -36.8% | -8.3% |
| YoY Change | — | — | — | — | — | — | — | >999% | +776.4% | +27.7% | -57.3% | -66.9% | -73.7% | -82.2% | -79.7% | -78.8% | -78.7% | -72.1% | -76.9% | -71.1% |